Corona Remedies IPO Day 1 LIVE: Issue Subscribed 61% — GMP, Subscription Status, and Expert Review. Should You Apply?

On Monday, December 8, the IPO of Corona Remedies attracted large numbers of investors, which made a good start for its bidding period of three days. The company's firm financial figures and a strong position in special pharmaceutical sectors have led to the Day 1 issue getting a subscription of 61%, indicating good demand from retail and NII investors.

The pharmaceutical company, which is recognized for its therapeutic area in women's health, cardiology, pain, and cancer and chronic diseases, is going public with a total offer of sales (OFS) of ₹655.37 crores.

Here’s everything you need to know: GMP trends, subscription updates, financials, and whether you should apply.

Corona Remedies IPO: Key Details at a Glance

IPO Open Date: December 8, 2025

Closing Date: December 10, 2025

Likely Allotment: December 11

Listing Date: December 15 (BSE & NSE)

Price Band: ₹1,008 – ₹1,062 per share

Issue Size: ₹655.37 crore (entirely OFS of 61.71 lakh shares)

Lot Size: 14 shares

Minimum Retail Investment: ₹14,868

BRLM: JM Financial

Registrar: Bigshare Services Pvt. Ltd.

Corona Remedies IPO GMP Today

Investor sentiment remains strong in the grey market. The GMP (Grey Market Premium) for Corona Remedies IPO today stands at ₹290 per share, which indicates a 27.31% higher return on listing from the upper price band.

This means that the estimated grey-market price is ₹1,352 per share.

Corona Remedies IPO Subscription Status (Day 1 LIVE)

As of the first day of bidding:

Overall Subscription: 61%

Retail Investors: Sales 56%–63% booking in preliminary updates

NII Category: 41%–46% subscribed

QIB Category: No bid on Day 1

27,98,502 shares were bundled for a total of 45,71,882 shares in the afternoon.

Why Are Investors Showing Interest?

1. Strong Revenue and Profit Growth

Corona Remedies has done stellar growth:

Revenue increased from ₹884 crore (FY23) → ₹1,196 crore (FY25)

16.3% CAGR

EBITDA surged from ₹135 crore → ₹246 crore

PAT went up from ₹85 crore → ₹149 crore

Steady and strong growth has made the company’s investment appeal even stronger.

2. Outperformance in the Indian Pharma Market

From June 2022 to June 2025:

Corona Remedies achieved 16.77% CAGR

This is 1.82× the average of the Indian Pharmaceutical Market (IPM)

The volume growth of 5.70% was significantly above IPM’s 2.15%

Performance in chronic therapies and brand recall raise it among the mid-sized pharma players.

3. High GMP and Strong Retail Traction

A GMP of almost ₹300 conveys a strong message: retailers are positive and the stock would probably get good listing gains.

4. Premium Valuation Justified? Analysts Weigh In

Brokerages such as Swastika Investmart and Canara Bank Securities recommended a 'Subscribe' rating based on:

Leading position in women’s health & management of pain

Great M&A execution (Myoril brand grew 3x after acquisition)

96% India-centered revenue (minimal US FDA risk)

Backward integration via hormone API manufacturing

However, it is priced at 43x P/E, thus investors must think of long-term rather than just short-term expectations.

Should You Subscribe to Corona Remedies IPO?

Analyst Verdict: Subscribe for Long-Term Gains

Analysts are divided into two camps regarding the IPO:

past performance's strength

future growth visibility

good positioning in the market

high GMP and interest from investors

presence in therapy with potential for scaling up

Because the entire offer is OFS, the company will not get the money but its fundamentals will be added to the pool.

Best for long-term high-risk investors.